1. Annual Report 2025
  2. Research
  3. GRECAP

GRECAP

Cardiovascular Research Group In Primary Care (GRECAP)

The group is made up of seven family doctors, a preventive doctor and a graduate in Statistics, all working in Barcelona. 44% of its members are women. There are four doctors, two of whom are women and one more is finishing her doctoral thesis. 

The group has a recognized track record and was accredited as consolidated by AGAUR in 2021 (2021 SGR 01417). Within the group, several doctoral theses have been defended and another three are currently in progress.

The group's lines of work are specifically:

1.- Heart Failure in Primary Care: Knowledge, attitudes and skills of patients and professionals regarding the management of heart failure. Evaluation of interventions.
2.- High blood pressure and cardiovascular risk.
3.-Primary and secondary cardiovascular prevention.

Group projects

  • Validació externa de l'algoritme de risc del projecte "Valor pronòstic del monitoratge ambulatori de pressió arterial de 24 hores sobre la morbiditat i mortalitat cardiovascular en pacients en prevenció primària cardiovascular". ICS - Institut Català de la Salut. 2022-2025. IP: Ernest Vinyoles Bargalló.

  • Reproductibilitat ecogràfica dels criteris de voltatge d'HVE i de les alteracions del segment ST-T. ICS - Institut Català de la Salut. 2008-2025. IP: Ernest Vinyoles Bargalló.

  • Relación entre el Score H2PEF y la morbimortalidad de los pacientes con insuficiencia cardíaca con fracción de eyección. ICS - Institut Català de la Salut. 2022-2025. IP: José María Verdú Rotellar.

  • Proyecto PEEADE-SIDIAP: Seguimiento cardiovascular a largo plazo mediante SIDIAP de una cohorte sin enfermedad cardiovascular representativa de la población mayor de 64 años. Consorcio Centro de Investigación Biomédica en RED (CIBER). 2022-2025. IP: José María Verdú Rotellar.

  • Impacto de un programa orientado a mejorar la fragilidad en los pacientes con cardiopatía isquémica estable en atencion primaria:estudio FRAGICOR. ICS - Institut Català de la Salut. 2025-2028. IP: Miguel Angel Muñoz Pérez.

  • Impacte d'un programa orientat a millorar la fragilitat en pacients amb cardiopatia isquèmica estable en atenció primària: estudi Fragicor. ICS - Institut Català de la Salut. 2025-2027. IP: Miguel Angel Muñoz Pérez.

  • Hipertensió Ortostàtica, Pressió Ambulatòria i Fenotips Hipertensius. 2022-2026. IP: Ernest Vinyoles Bargalló.

  • Estratificación pronóstica a muy corto plazo de la insuficiencia cardiaca descompensada en Atención primaria: Hefestos 3.7 Score. (PI23/01422). Instituto de Salud Carlos III. 2024-2026. IP: José María Verdú Rotellar.

  • Ensayo de superioridad de fase III, doble ciego, aleatorizado y con grupos paralelos para evaluar la eficacia y la seguridad del uso combinado de vicadrostat (BI 690517) y de empagliflozina por vía oral en comparación con placebo y empagliflozina en participantes con diabetes tipo 2, hipertensión y enfermedad cardiovascular establecida. (1378-0041). Boehringer Ingelheim España, S.A. 2025IP: Ernest Vinyoles Bargalló.

  • Efecte de la música sobre la presió arterial ambulatòria. Assaig clínic pragmàtic (MINAMUSIC). 2024-2025. IP: Ernest Vinyoles Bargalló.

  • An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19. (Insight 12). University of Minnesota. 2021-2025. IP: Ernest Vinyoles Bargalló.

  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatmentof COVID-19 in Participants With High-Risk for Disease Progression. (GS-US-611-6273). Gilead Sciences, S.L. 2023IP: Ernest Vinyoles Bargalló.

  • A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension. (CXXB750B12201). Novartis Farmacéutica, S.A. 2023IP: Ernest Vinyoles Bargalló.

  • Models pronòstics de morbimortalitat de la insuficiència cardíaca estable i descompensada en Atenció Primària. (Predoc_Eco-23/8). ICS - Institut Català de la Salut; Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2029. IP: Maria Antònia Pou Giménez,Victoria Cendrós Cámara.

Group Publications

  • Cendrós V, Verdú Rotellar JM, Parra J, Muñoz MA, Domingo M, Franch J. Usefulness of the H2FPEF score in the diagnosis and prognosis of heart failure with preserved ejection fraction in primary care. Aten. Prim. 2025;57(12):103335-103335. PMID:41061642.

  • Soldevila Bacardit N, Vinyoles Bargalló E. The reference arm - The eternal doubt. Hipertens. Riesgo Vasc. 2025;42(1):1-2. PMID:39818453.

  • Cendros V, Domingo M, Navas E, Munoz MA, Bayes Genis A, Verdu Rotellar JM. Rehospitalization, mortality and associated variables in primary care patients with heart failure and preserved ejection fraction after first hospitalization. Int. J. Cardiol. Cardiovasc. Risk Prevention. 2025;25200391-200391. PMID:40160695.

  • Haro Montoya M, Caballol Angelats R, Fernández Sáez J, Montelongo Sol M, Conangla Ferrin L, Cendrós Cámara V et al. Prognostic Utility of HEFESTOS Score and Complementary Lung Ultrasound for Heart Failure Decompensation in Primary Care Outpatients: A Prospective Cohort Study. J. Cardiovasc. Dev. Dis. 2025;12(9): PMID:41002626.

  • Porta M, Pumarega J, Aguilar R, Prieto Merino D, Campi L, Rius C et al. Prepandemic levels of cytokines and immunoglobulins and risk of SARS-CoV-2 infection and COVID-19 in the general population of Barcelona. Front. Public Health. 2025;131548456-1548456. PMID:40910046.

  • de la Sierra A, Ruilope LM, Staplin N, Stergiou GS, Vinyoles E, Williams B. Mortality risks in different subtypes of white-coat hypertension: implications for the diagnosis of white-coat hypertension. J. Hypertens. 2025;43(8):1450-1456. PMID:40509659.

  • Gorostidi M, Böhm M, Ruilope LM, Staplin N, Vinyoles E, Segura J et al. Mortality according to ambulatory blood pressure in hypertensive patients with normal or impaired kidney function. Hypertens. Res. 2025;48(12):3234-3243. PMID:41062620.

  • López Laguna N, Toledo E, Hershey MS, Babio N, Sorlí JV, Ros E et al. Life's Simple 7 and Risk of Peripheral Artery Disease: Results from the PREDIMED Study and an Updated Meta-Analysis. Nutrients. 2025;17(13): PMID:40647164.

  • Muñoz MA, Cendrós V, Navas E, Verdú Rotellar JM, Barrot J, Franch J. Incidence of first hospitalization for heart failure in type 2 diabetes mellitus: A population-based cohort study in primary care. Prim. Care Diabetes. 2025;19(5):471-477. PMID:40764218.

  • Cendrós V, Domingo M, Navas E, Muñoz MÁ, Bayés Genís A, Verdú Rotellar JM. Impact of Sex on Rehospitalization Rates and Mortality of Patients with Heart Failure with Preserved Ejection Fraction: Differences Between an Analysis Stratified by Sex and a Global Analysis. J. Pers. Med. 2025;15(7): PMID:40710414.

  • de la Sierra A, Vinyoles E, Gorostidi M, Segura J, Ruilope LM. Impact of Office and Ambulatory Blood Pressure on Mortality in Patients with Coronary Heart Disease. Cardiol. Ther. 2025;14(4):635-649. PMID:41076499.

  • Yun S, Comín Colet J, Calero Molina E, Hidalgo E, José Bazán N, Cobo Marcos M et al. Evaluation of mobile health technology combining telemonitoring and teleintervention versus usual care invulnerable-phase heart failure management (HERMeS): a multicentre, randomised controlled trial. Lancet Digit. Health. 2025;7(5):100866-100866. PMID:40374486.

  • Mesa A, Franch Nadal J, Navas E, Mauricio D. Cardiovascular disease in women with type 1 diabetes: a narrative review and insights from a population-based cohort analysis. Cardiovasc. Diabetol. 2025;24(1):217-217. PMID:40399939.

Proceeding Papers

  • de la Sierra A, Ruilope L, Staplin N, Stergiou GS, Vinyoles E, Williams B. Mortality Risks in Subtypes of White-Coat Hypertension: Implications for the Diagnosis of White-Coat Hypertension. J. Hypertens. 2025;43(SUPPL 1)

  • De la Sierra A, Gorostidi M, Bohm M, Ruilope L, Staplin N, Vinyoles E et al. Mortality According to Clinic and Ambulatory Blood Pressure in Hypertensives Patients with Normal or Impaired Kidney Function. J. Hypertens. 2025;43(SUPPL 1)

  • Vinyoles E, Donatiu P, Tafalla M, Pelegrin M, Vanrell M, Soldevila N et al. Effect of Music on Home Blood Pressure Self-Measurements: A Pragmatic Pilot Clinical Trial. J. Hypertens. 2025;43(SUPPL 1)

  • Priego Artero M, Cecilia Salgueiro M, Torras Borrell J, Rebagliato Nadal O, Benítez Camps M, Rosinach Bonet J et al. Comparison About Special Situations Between 2021 National Hypertension Guidelines and 2023 European Society of Hypertension Guidelines. J. Hypertens. 2025;43(Suppl 1):203-204.

Anar a l'inici